Identification of patients at high risk of secondary extramedullary multiple myeloma development. (2nd November 2021)

• Record Type: Journal Article
• Authors: Stork, Martin; Sevcikova, Sabina; Minarik, Jiri; Krhovska, Petra; Radocha, Jakub; Pospisilova, Lenka; Brozova, Lucie; Jarkovsky, Jiri; Spicka, Ivan; Straub, Jan; Pavlicek, Petr; Jungova, Alexandra; Jelinek, Tomas; Sandecka, Viera; Maisnar, Vladimir; Hajek, Roman; Pour, Ludek
• Is Part Of: British journal of haematology. Volume 196:Number 4(2022)
• Page Start: 954
• Page End: 962
• Publication Date: 2021-11-02
• Subjects: multiple myeloma -- extramedullary disease -- prognostic factors; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17925
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4·38, 95% confidence interval (CI): 2·46–7·80, P < 0·0001], high lactate dehydrogenase (LDH) levels (>5 μkat/l; OR 2·07, 95% CI: 1·51–2·84, P < 0·0001), extensive osteolytic activity (OR 2·21, 95% CI: 1·54–3·15, P < 0·001), and immunoglobulin A (IgA; OR 1·53, 95% CI: 1·11–2·11, P = 0·009) or the non‐secretory type of MM (OR 2·83; 95% CI: 1·32–6·04, P = 0·007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression‐free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13·8 months (95% CI: 11·4–16·3) vs 18·8 months (95% CI: 17·7–19·9), P = 0·006; mOS: 26·7 months (95% CI: 18·1–35·4) vs 58·7 months (95% CI: 54·8–62·6), P < 0·001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.